Find Clinical Trials

Inclusion Criteria: 1. Age 22-85 years 2. Refractory glaucoma describes eyes diagnosed with glaucoma specific to one of the following: * uncontrolled by maximally tolerated medical therapy * failed one or more incisional intraocular glaucoma surgeries (e.g., glaucoma filtering surgery or tube shunt) * failed one or more cilioablative procedures (e.g., cryotherapy, cyclodiode therapy) * or have any other condition (e.g., conjunctival scarring, uveitis) in which conventional incisional glaucoma surgery like trabeculectomy would be more likely to fail than for an eye with uncomplicated primary open angle glaucoma. 3. Primary open-angle or traumatic glaucoma. 4. Medicated DIOP ≥25 mmHg and ≤45 mmHg on maximum-tolerated medical therapy that is stable for at least 30 days. 5. Best-corrected baseline visual acuity of light perception or better in study eye. 6. Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities: * Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially at the inferior or superior poles with or without disc hemorrhage; * Localized abnormalities of the peripapillary retinal nerve fiber layer, especially at the inferior or superior poles; or * Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue 7. Visual field mean deviation (MD) by Humphrey Visual Field: Visual field defects consistent with glaucomatous optic nerve damage and mean deviation worse than -3 dB in the study eye; and at least one of the following two findings: * A cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level on the pattern deviation (PD) plot; * Glaucoma hemi-field test "outside normal limits". 8. At least two contiguous clock hours of intact conjunctiva near the limbus between clock hours of 10:00 and 02:00 in the study eye. 9. Adequate space in the anterior chamber by Spaeth Grade C, D or E for iris insertion (with indentation). 10. Participant has the understanding, ability, and willingness to fully comply with study procedures and postoperative care instructions. 11. Participant understands, is capable and competent to sign the informed consent. Exclusion Criteria 1. Active neovascular conditions such as active iris or corneal neovascularization, or active proliferative retinopathy in study eye. 2. Pigmentary glaucoma in study eye. 3. Angle-closure glaucoma in study eye. 4. Pseudoexfoliation syndrome in study eye 5. Iridocorneal endothelial syndrome in study eye. 6. Uveitic glaucoma in the study eye. 7. Epithelial or fibrous downgrowth in the study eye. 8. Corneal conditions in study eye inhibiting normal incisional healing (e.g. Fuch's dystrophy) or impair visualization of implant inside the anterior chamber. 9. Prior intraocular surgery in study eye within ≤6 months before the preoperative visit (including phacoemulsification). 10. Central corneal endothelial cell count of less than 1600 cells/mm2 in study eye. 11. Anticipated need for ocular surgery or retinal laser procedure in the study eye within the 12-month follow-up period. 12. Need for glaucoma surgery combined with other ocular procedures in study eye at implant (e.g. cataract surgery, penetrating keratoplasty, or retinal surgery). 13. Unwilling to discontinue contact lens use in the study eye after surgery. 14. Central corneal thickness ≤490μm or ≥620μm in the study eye. 15. Clinically significant inflammation or infection in the study eye within 60 days prior to the preoperative visit (e.g., blepharitis, conjunctivitis, keratitis, uveitis, herpes simplex infection) or any systemic infection. For purposes of this study, clinically significant is considered any such condition requiring prescription therapy. 16. Any condition that prevents the device implantation in the superior region of the study eye. 17. Vitreous in the study eye anterior chamber for which a vitrectomy is anticipated. 18. Functionally significant cataract in the study eye. 19. Other clinical conditions: 1. Poorly controlled diabetes (Type I or Type II) as determined by HbA1c \>8 within 3 months of implant. 2. Cancer requiring treatment during the duration of the study. 3. Any drugs (e.g.: immunosuppressive drugs) or co-morbidity that might inhibit wound healing. 20. Participation in any other clinical study during participation in this study. 21. Engage in activities that involve submerging their head under water, such as diving or swimming. 22. Women who are (i) pregnant, (ii) nursing, (iii) planning a pregnancy and (iv) of childbearing potential not using a reliable method of contraception. 23. Life expectancy \<1 year. Note: If both eyes are eligible, the eye with the worse BCVA should be selected

Inclusion Criteria: * (1) be receiving or eligible to receive services at the recruitment sites * (2) read and speak English * (3) be at least 50 years old * (4) have at least moderate depressive symptoms at screening (≥ 8 on the Patient Health Questionnaire-9 \[PHQ-9\]). * (5) Participants who are NOT currently receiving outside therapy must agree NOT to start outside therapy during study participation. Participants who are currently receiving outside therapy must agree NOT to increase their outside therapy frequency during study participation. Exclusion Criteria: * (1) probable dementia based on the Blessed Orientation and Memory Scale. * (2) moderate or high risk of suicide based on the 6-item Columbia-Suicide Severity Rating Scale * (3) a terminal illness with less than six months to live or unstable physical health conditions based on self-report * (4) a diagnosis of a psychotic disorder like schizophrenia or bipolar disorder based on self-report and medical chart review * (5) severe vision impairment based on self-report (i.e., legally blind) * (6) current substance use disorders or receiving substance use treatment. * (7) currently receiving outside therapy more frequently than once a month or have started a new therapy treatment less than 3 months ago

Inclusion Criteria: * Individuals aged 20 years and above. * Participants residing in the randomized clusters of Karachi, Pakistan * Individuals willing to participate in the study and provide consent. * Both individuals with normoglycemia, intermediate hyperglycemia, and diabetes are encouraged to participate. * Participants who can attend the scheduled meetings and interventions as per the study protocol. Exclusion Criteria: * Individuals below the age of 20 years. * Individuals unwilling to provide consent for participation. * Participants with severe health conditions that may hinder their active involvement in the study. * Individuals with non-compliance with research protocols

Inclusion Criteria: 1. age 55 and older 2. Type 2 Diabetes (documented by chart review, presence of treatment for type 2 Diabetes, fasting plasma glucose equal or greater than 126 mg/dL or A1C equal or greater than 6.5%). Exclusion Criteria: (1) HbA1c \&lt;6.5% or \&gt;9.0%, (2) body mass index \&gt; 40 kg/m2, (3) insulin-dependent Type 1 Diabetes Mellitus, (4) incident cardiovascular events in the last year (heart attack, stroke), (5) symptomatic coronary artery disease and/or heart failure, (6) uncontrolled hypertension (systolic blood pressure \&gt;150 mmHg and/or diastolic blood pressure \&gt;110 mmHg), (7) hypotension (resting systolic BP \&lt; 90 mmHg), (8) use of walking aid other than a cane, (9) active cancer, (10) impaired thermal sensation in the legs, (11) unable to fit into water-circulating garments, (12) orthopedic complications that preclude completion of physical function tests, (13) contraindications or inability to undergo a DXA scan, including implants, devices, or other foreign material, and inability to attain correct position and/or remain motionless for the measurement.

Inclusion Criteria: 1. Meet the diagnostic criteria of AIS according to the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018 2. Aged 18 to 75 years old 3. Stroke within 7 days of onset 4. Sign informed consent, provide relevant medical history information and provide biological specimens Exclusion Criteria: 1. Severe impairment of consciousness (awareness score of NIHSS\>1) 2. History of stroke within 12 months 3. Severe systemic disease including malignancy 4. ALT or AST\> 2 times the upper limit of normal or severe liver disease 5. creatinine \> 1.5 times the upper limit of normal or severe kidney disease 6. History of long-term drinking, drug use, and chemical poisoning (e.g., pesticide poisoning); Note: Long-term alcohol consumption, usually more than 5 years, over 40 g/day of alcohol for men and 20 g/day for women, or a history of heavy alcohol consumption within 2 weeks, over 80 g/day of alcohol 7. History of intestinal tumors, irritable bowel syndrome or inflammatory bowel disease or confirmed in the hospital 8. Unable to collect a stool specimen within 4 days of admission 9. Assessed to be unsuitable for participation in this study by the investigator

Inclusion Criteria: * Amenorrhea for at least 12 months * Controlled hypertension Exclusion Criteria: * Decompensated hypertension in stages 2 and 3 * Having a history of stroke or acute myocardial infarction * Smoker * Having a diagnosis of Diabetes Mellitus * Using hormone therapy.

Inclusion Criteria: Patients: * Age \>=18years * Informed Consent as documented by signature * One (or more) chronic medical condition/s (e.g., diabetes, asthma, cardiovascular or respiratory diseases, etc.) Healthy volunteers * Age \>=18years * Informed Consent as documented by signature * No diagnosed chronic medical condition Exclusion Criteria: Patients * Previous enrolment into the current study, * Cardiac pacemaker or another implanted electrical device * Women who are pregnant or breastfeeding * Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, delirium etc. of the participant Healthy volunteers: * Previous enrolment into the current study, * Cardiac pacemaker or another implanted electrical device * Women who are pregnant or breastfeeding * Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, delirium etc. of the participant * Presence of diagnosed chronic medical condition

Inclusion Criteria: * Patients with AR, BA and CARAS who meet the Western medical diagnostic criteria; * Chinese medical evidence consistent with lung qi deficiency evidence, phlegm-heat congestion of the lung evidence, or wind-heat offending the lung evidence; * Age 18 to 80 years; * Voluntarily accepted the study and signed an informed consent form; * Not participated in other clinical studies within 1 month before enrollment. Exclusion Criteria: * Patients with combined vasomotor rhinitis and eosinophilic non-allergic rhinitis, other non-allergic rhinitis diseases that can cause symptoms such as nasal congestion and runny nose; * Patients who are participating in other drug trials; * Patients with a combination of other serious systemic diseases; * Pregnant or lactating women; * Patients with confusion, disorders of consciousness, dementia, and various psychiatric disorders.

Inclusion Criteria: * Body mass index of 18-25 and 30-45 kg/m2 * Able to understand written and spoken English and/or Spanish * Fasting euinsulinemia (fasting serum insulin of 4-10 μU/mL) for reference group or hyperinsulinemia (fasting serum insulin ≥ 13 μU/mL) for hyperinsulinemic group on screening labs * Written informed consent (in English or Spanish) and any locally required authorization (e.g., Health Insurance Portability and Accountability Act) obtained from the participant prior to performing any protocol-related procedures, including screening evaluations. Exclusion Criteria: * Unable to provide informed consent in English or Spanish * Unwillingness to use only bedpan or urinal to void or to refrain from non-emergent mobile device use during the GIST * Documented weight loss of ≥ 5% of baseline within the previous 6 months * Systolic blood pressure \< 90 mm Hg or \> 160 mm Hg, and/or * Diastolic blood pressure \< 60 mm Hg or \> 100 mm Hg * Abnormal resting heart rate: \< 60 or ≥ 110 bpm * Sinus brady or tachycardia that has been worked up and considered benign by the recruit's personal physician may be permitted at the PI's discretion * Abnormal screening electrocardiogram (or if on file, performed within previous 90 d): * Non-sinus rhythm * Heart conduction blocks * Previously unknown ischaemic changes that persist on repeat EKG: * ST elevations * T-wave inversions in a vascular distribution * Hemoglobin A1c ≥ 5.7%, and/or * Fasting plasma glucose ≥ 100 mg/dL * Positive qualitative β-hCG (i.e., pregnancy test) in women of childbearing potential * Positive urine drug screen, except for lawfully prescribed medications and/or marijuana, provided that participant agrees to refrain from marijuana use during the period that they refrain from alcohol. * Transaminases (AST or ALT) \> 3.0 x the upper limit of normal * Total bilirubin \> 1.25 x the upper limit of normal * Abnormal sodium, potassium, chloride, or bicarbonate levels that are considered potentially significant according to the clinical judgment of the PI. * Creatinine equating to estimated glomerular filtration rate \< 60 mL min-1 1.73 m-2 * Hemoglobin \< 10 g/dL or hematocrit \< 30% * Platelet count \< 100,000/μL * Women currently pregnant, measured by serum and/or urine β-hCG * Women currently breastfeeding * History of having met any of the American Diabetes Association's definitions of prediabetic state during adulthood or diabetes mellitus (i.e., overt diabetes) at any time: * Hemoglobin A1c ≥ 5.7%, or rapid rise in documented HbA1c values causing clinical concern for evolving insulin deficiency * Plasma glucose ≥ 100 mg/dL after 8-h fast * Plasma glucose of ≥ 140 mg/dL at 2 h after ingestion of a 75-g glucose load * Random plasma glucose ≥ 200 mg/dL associated with typical hyperglycemic symptoms, diabetic ketoacidosis, or hyperglycemic-hyperosmolar state * History of gestational diabetes mellitus within the previous 5 years * Use of most antidiabetic medications within the 30 days prior to screening * Excluded: thiazolidinediones, sulfonylureas, meglitinides, DPP4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, amylin mimetics, acarbose, insulin * Metformin is acceptable provided that recruits meet all of the inclusion criteria at screening * Known, documented history, at the time of screening, of any of the following medical conditions: * Pancreatic pathology, including but not limited to: Pancreatic neoplasia (unless appropriately evaluated and considered benign and not producing hormones), Chronic pancreatitis, History of acute pancreatitis within the past 5 years * Cardiovascular diseases (N.B. uncomplicated hypertension is not exclusionary) * Atherosclerotic cardiovascular disease * Stable or unstable angina * Myocardial infarction * Ischaemic or hemorrhagic stroke * Peripheral arterial disease (claudication) * Use of dual antiplatelet therapy (aspirin + P2Y12 inhibitor) * History of percutaneous coronary intervention * Heart rhythm abnormalities (non-sinus) * Congestive heart failure of any New York Heart Association class * Severe valvular heart disease (e.g., aortic stenosis) * Pulmonary hypertension * Chronic kidney disease, Stage 3 or higher (estimated glomerular filtration rate \< 60 mL/min/1.73 m2), of any cause * Advanced or severe liver disease, including but not limited to: * Advanced liver fibrosis, as determined by non-invasive testing * Cirrhosis of any etiology * Autoimmune hepatitis or other rheumatologic disorder affecting the liver * Biliopathy (e.g., progressive sclerosing cholangitis, primary biliary cholangitis) * Hepatocellular carcinoma * Infiltrative disorders (e.g., sarcoidosis, hemochromatosis, Wilson disease) * Gallstone disease, including: * Biliary colic (active) * History of acute cholecystitis not treated with cholecystectomy * History of other gallstone complications (e.g., pancreatitis, cholangitis) * Chronic viral illness (N.B. diagnosis based only on medical history and not by laboratory confirmation) * Hepatitis B virus (HBV), unless previously successfully eradicated with antiviral drugs that have been discontinued for at least 30 d prior to screening * Hepatitis C virus (HCV) infection, unless previously successfully eradicated with antiviral drugs that have been discontinued for at least 30 d prior to screening * Human immunodeficiency virus (HIV) infection * Active seizure disorder (including controlled with antiepileptic drugs) * Psychiatric diseases causing functional impairment that: * Are or have been decompensated within 1 year of screening, and/or * Require use of anti-dopaminergic antipsychotic drugs associated with significant weight gain/metabolic dysfunction (e.g., clozapine, olanzapine), monoamine oxidase inhibitors, tricyclic antidepressants, or lithium * Other endocrinopathies: * Cushing syndrome (okay if considered in remission after treatment, provided that no exogenous corticosteroids or other ongoing treatment are required) * Adrenal insufficiency * Primary aldosteronism * Venous thromboembolic disease (deep vein thrombosis or pulmonary embolism) or any required use of therapeutic anticoagulation * Bleeding disorders, including due to anticoagulation, or significant anemia * Active malignancy, or hormonally active benign neoplasm, except allowances for: * Non-melanoma skin cancer * Differentiated thyroid cancer (AJCC Stage I only) * Clinical concern for increased risk of volume overload, including due to medications and/or heart/liver/kidney problems, as listed above * Clinical concern for increased risk of hypokalemia, including low potassium on screening labs (i.e., below lower limit of normal), use of certain medications, or any medical conditions listed above * Use of prescribed medications used for any of the indications in the preceding list of excluded conditions, or their use within 30 d prior to screening, except allowances for: * Use of drugs prescribed for indications other than the exclusionary diagnoses/purposes listed above (e.g., antiepileptic drugs used for non-seizure indications, ACEi/ARB used for uncomplicated hypertension rather than for congestive heart failure, etc.). Note, as above, that antidiabetic drugs except metformin within 30 d of screening are excluded. * Oral or parenteral corticosteroids (at greater than prednisone 5 mg daily, or equivalent) for more than 3 days within the previous 30 days; topical and inhaled formulations are permitted. * Beta blockers or non-dihydropyridine calcium channel blockers (verapamil or diltiazem) * History of certain weight-loss (bariatric) surgery, including: * Roux-en-Y gastric bypass * Biliopancreatic diversion * Restrictive procedures (lap band, sleeve gastrectomy) performed within the past 6 months * Clinical concern for alcohol overuse, including recent documented history during screening and/or participant report of regularly consuming more t

Inclusion Criteria: * African American/Black males * age 18 years or older * ambulatory status * diagnosis of Type 2 Diabetes (T2D) for one year duration or longer * be under the care of a physician for their diabetes, self report an A1C of 7.0% or more in the last year * be willing to participate in study events (weekly physical activity, exercise and CBT sessions, group discussion sessions, and in-person health assessments) * have reliable internet access (steady internet connection or unlimited data) that will allow them to use a tablet/phone/computer to complete study related tasks * live in the Wayne or Washtenaw County\\ * have reliable transportation to in-person events Exclusion Criteria: * stage 2 hypertension as defined by Joint National Committee (JNC) VIII * recent cardiac events * recent laser surgery for proliferative retinopathy * history of stroke * lower limb amputation * peripheral neuropathy * severe Chronic Obstructive Pulmonary Disease (COPD) (e.g., basal oxygen) * class III or IV heart failure * medical instability. Per American College of Sports Medicine (ACSM) guidelines, medical exclusion criteria will also include currently experiencing: * ongoing unstable angina * uncontrolled cardiac arrhythmia with hemodynamic compromise * active endocarditis * symptomatic severe aortic stenosis * acute myocarditis or pericarditis * acute aortic dissection * acute pulmonary embolism * pulmonary infarction * deep venous thrombosis * physical disability that precludes safe and adequate testing * chest discomfort with exertion * unreasonable breathlessness, or dizziness, fainting, or blackouts. As part of the screening process, the investigators will ask the participant to self-report on these conditions. Participants who are currently receiving psychotherapy services for the treatment of depression from a mental health provider will be excluded. Participants who are currently receiving only medication management from a psychiatrist will be included. If you are interested in the study, please complete our screening survey: https://redcapproduction.umms.med.umich.edu/surveys/?s=JNPPEDANX7KLPPF9. Thank you so much!

Inclusion Criteria: * Current resident of the household in which an index participant lives * Willing to complete data collection protocols * Fluent in written and spoken English Exclusion Criteria: \-

Inclusion Criteria: Participants must meet all the following criteria to be included in the trial: * Aged 18 to 85 years inclusive, at Screening * Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR \[if single episode, duration of ≥4 weeks and ≤24 months\] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60. * Depression is of moderate to severe degree at Screening and Baseline, independently confirmed by additional clinical assessments * Participant has been on a stable dose of a single antidepressant medication at an adequate dose (label specified) for an adequate duration in the last month prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator. * Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤ 40 kg/m2), inclusive, at Screening. * Participant is able to refrain from nicotine use during the dosing session (up to 8 hours) * Registered with a healthcare professional who can confirm the diagnosis and previous treatments received by the participant. * Participants capable of producing sperm must use a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential. * Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception (i.e., failure rate less than 1% when used consistently and correctly) in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day 1 prior to dosing. * Female participants who were capable of producing eggs (ova) must agree that the only exclusion from the requirement for contraception during the trial is to be postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy. Postmenopausal is defined as spontaneous amenorrhea for at least 12 months, and a serum follicle-stimulating hormone level in the menopausal range, unless the participant is taking hormone replacement therapy or is using hormonal contraception. * Participant has provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form. Exclusion Criteria: Participants with any of the following characteristics/conditions will be excluded from trial participation: * Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, current or previous history of bipolar disorder, or current borderline personality disorder. * Participants with a medical diagnosis of attention deficit hyperactivity disorder (ADHD) will be excluded if currently taking medication for ADHD * Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first degree relatives). * Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening. * Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose (label specified) for an adequate duration as judged by the Investigator and clinical interview. * Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months. * Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressant, mirtazapine, trazodone, moclobemide, buspirone, ketamine or S-ketamine, or an antipsychotic or mood stabilizer for MDD. Note: if receiving these medications for another indication, they must be discontinued ≥ 14 days or 5 half-lives, whichever is longer, prior to Day 1. * Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 10 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening. * Participant report of (or if available in medical record) treatment with ketamine or S-ketamine use within 6 months prior to Screening. * Clinically relevant history of abnormal physical health interfering with the trial as determined by medical history and physical examinations obtained during Screening as judged by the Investigator (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal \[including dyspepsia or gastroesophageal reflux disease\], hepatic, or renal disorder). * Participants with renal insufficiency. * Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication. * Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate or blood pressure * History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism, or excretion of the trial medication. * Participant has a presence or relevant history of organic brain disorders (e.g., epilepsy, seizure, intracranial hypertension, intracranial bleed and aneurysmal disease, brain tumor or other medical conditions associated with seizures or convulsions). * Known sensitivity to psilocin and/or any excipients present in the formulation. * Participant is taking or has taken OTC doses of 5-HTP or St John's Wort within 14 days prior to trial medication administration. * The participant has participated in a clinical trial and has received a medication or a new chemical entity within 12 weeks prior to dosing with the current trial medication. Participants who have completed observational or non-interventional studies will be allowed. * Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing. * Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing. * History of serotonin syndrome. * Unwilling to consent to audio and video recording of psychological support and dosing sessions. * Staff and family members of Cybin IRL Limited, investigator sites, contract research organization or other vendors.

Inclusion Criteria: 1. Participants with Solid Tumors * Histopathologically confirmed diagnosis of an advanced, unresectable, or metastatic solid tumor (ovarian, pancreatic, urothelial, renal, hepatocellular, gastrointestinal (GI), lung, prostate, and breast cancer). * Have progressed despite standard therapies, or for whom conventional therapy is not effective or tolerable, as judged by the Investigator. Patients must have no available therapeutic options known to confer clinical benefit for their tumor type. 2. Participants with Multiple Myeloma * Have progressed despite standard therapies, or for whom conventional therapy is not effective or tolerable, as judged by the Investigator. * Patients must have failed at least 3 prior therapies for myeloma and should have had prior exposure to a proteosome inhibitor, an IMiD, and an anti-CD38-directed therapy. 2\. Male or female participants ≥18 years of age at the time of informed consent 3. An Eastern Cooperative Oncology Group (ECOG) performance status scale of 0, 1, or 2 at Screening 4. Must have at least 1 measurable lesion by RECIST version 1.1 (solid tumors only), or evaluable disease by IMWG Uniform Response Criteria (multiple myeloma only) 5. Adequate organ function and bone marrow reserve 6. Adequate cardiac function as estimated by left ventricular ejection fraction 7. Female participants of child-bearing potential must: * Have a negative serum pregnancy test at screening and a negative pregnancy test at Week 1 Day 1 prior to first dose of QXL138AM, AND * Agree to use at least 1 highly effective method of contraception for the duration of study participation, and for 120 days after last dose of QXL138AM. 8\. Male participants of child-bearing potential must: * Agree to use at least 1 highly effective method of contraception for the duration of study participation, and for 120 days after last dose of QXL138AM, AND * Refrain from sperm donation prior to the first dose of investigational product through 120 days following the last dose of QXL138AM. Exclusion Criteria: 1. New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, a history of risk factors for Torsades de Pointes (TdP), including heart failure, hypokalemia, and family history of long QTc syndrome, or evidence of ischemia on ECG. Symptomatic ischemic heart disease or unstable angina pectoris; or history of cardiac angioplasty, cardiac stenting, or coronary artery bypass graft. A clinically significant baseline prolongation of QT/QTcF interval at screening. 2. The use of concomitant medications that may significantly prolong the QT/QTc interval. 3. Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy. 4. Known hypersensitivity to the investigational product or components (anti-CD138 IgG1 antibody, Interferon A2a and/or the formulation excipients: histidine, sucrose, arginine, polysorbate 80). 5. Female participant is lactating. 6. Any other clinically significant comorbidities. 7. Received prior anticancer therapy within 28 days or 5x the half-life (whichever is shorter) prior to the first dose of investigational product. 8. Participants who received wide-field radiation therapy within 4 weeks prior to first dose of investigational product, (2 weeks for limited field radiation therapy) 9. Major surgery within 30 days before first dose of investigational product 10. Chronic use of systemic corticosteroids of more than 20 mg/day of prednisone or equivalent. 11. Active, clinically significant liver disease such as Hepatitis B or C, autoimmune hepatitis, or cirrhosis (Child Hugh Stage B or C). 12. Current or history of mood disorder such as major depression per DSM-5 within past two years not controlled with current therapy. 13. Active autoimmune disorders not controlled with current therapy. 14. Active endocrine disorders including hypothyroidism, hyperthyroidism, hypoglycemia, hyperglycemia, and diabetes mellitus not controlled with current therapy.

Inclusion Criteria: * being an adult aged 18 or older residing in Kanepokhari Rural Municipality or Patharisanischare Municipality, * those detected through the CIDT * providing consent for participation * being proficient in speaking and understanding Nepali Exclusion Criteria: * people with already receiving mental health services * having severe mental illness\] * participants below the age of 18 years, * participants outside of Kanepokhari and Pathari-sanischare Municipality

Inclusion Criteria: * Women will be eligible to participate if they are 30 to 55 years old, due to receive both breast and cervical cancer screening during the study intervention implementation phase based on Kenyan guideline recommendations, not experiencing breast or cervical cancer symptoms (will be referred for diagnostic testing with facilitation support from the study team), not pregnant, fluent in a study language (English,Kiswahili, Kamba, Kalenjin, and Kikuyu) and plan to remain in the community for at least 2 years Exclusion Criteria: \-

Inclusion Criteria: 1. For all groups : * No alcohol or psychoactive substances such as coffee had been consumed in the 24 hours prior to the examination * MMSE≥24 points，MOCA≥26 points * No anti-infective drugs in the past 1 month, no cold, fever or other infection history in the past 2 weeks * Patients with diabetes had fasting controlled below 9.0mmol/L before the examination * Volunteer to participate in the study and sign the informed consent 2. For Recurrent depression patients: * Meet the Diagnostic criteria for recurrent major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) * Age 35-85 years old, gender is not limited * HAMD≥8 points 3. For first episode depression Patients: * Gender, age and education level were matched with the recurrent depression group * Meet the Diagnostic criteria for the first episode of depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) * HAMD≥8 points 4. For controls: * Healthy people undergoing "DPA-714 or FDG imaging PET/MRI" physical examination in PET/CT room of our hospital * Gender and education level were consistent with both the recurrent depression group and the first-episode depression group * never used any psychotropic drugs * HAMD\<8 points；HAMA\<7 points Exclusion Criteria(for all groups): * Have a history of organic mental disorders or other mental disorders * A family history of hereditary diseases * Persons with mental retardation or dementia * A history of psychoactive substance abuse * Can not cooperate with/complete the psychological examination scale * Previously found serious physical diseases (heart, brain, liver, lung and kidney) * MRI contraindications, abnormalities found in head CT or MRI * A history of drug or alcohol abuse * Have a history of metabolic diseases such as hyperthyroidism, hypothyroidism,and rheumatic diseases * are in the state of pregnancy or breastfeeding

Part 1a/1b Inclusion Criteria: A patient must meet all of the following inclusion criteria to be eligible to participate in this study. 1. Solid tumor malignancy meeting the following criteria: * Part 1a Dose Escalation and Part 1b New Formulation Dose Escalation/Pilot Food Effect Cohort: locally advanced or metastatic solid tumor malignancy that has progressed or was non responsive to available therapies and for which no standard or available curative therapy exists. * Part 1a and Part 1b Backfill: patients with TNBC, SCLC, and solid tumors harboring a RB1 or CDKN2A/B loss genomic alteration or Rb protein LoF. Additional tumor types or genomic alterations may be considered by the SRC as data become available. Patient must have progressed or was non-responsive to available therapies and for which no standard or available curative therapy exists 2. Measurable disease per RECIST v1.1. 3. Age ≥ 18 years. 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1. 5. Life expectancy \> 12 weeks. 6. Able to undergo a fresh biopsy if medically feasible. 7. Ability to swallow capsules by mouth. 8. Have the following laboratory values: 1. Calculated creatinine clearance (CrCl) ≥ 60 mL/min/1.73 m\^2 by Cockroft-Gault formula (actual body weight must be used for CrCl unless body mass index \[BMI\] is \> 30 kg/m2, then lean or ideal body weight must be used (based on institutional practice), or estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2 based alternative methods of determination (e.g., modification of diet in renal disease \[MDRD\], 24-hour urine collection) if consistent with local or institutional practice. 2. Total bilirubin ≤ 1.5 × upper limit of normal (ULN) unless prior history of Gilbert's syndrome with Sponsor Medical Monitor approval. 3. Aspartate transaminase and alanine transaminase ≤ 2.5 × ULN, or ≤ 5 × ULN if due to liver involvement by tumor. 4. Hemoglobin ≥ 9.0 g/dL (last transfusion \> 14 days prior to first dose of study drug). 5. Platelets ≥ 100 × 10\^9 cells/L (last platelet transfusion \> 14 days prior to first dose of study drug). 6. Absolute neutrophil count ≥ 1.2 × 10\^9 cells/L (last dose of hematopoietic growth factors \> 14 days from first dose of study drug). 9. Females of childbearing potential must commit to sexual abstinence or to use two acceptable forms of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, or any form of hormonal contraceptives) for the duration of the study and for four months following the last dose of study treatment. Females who are at least two years postmenopausal or premenopausal with documented hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or permanent infertility due to alternate medical causes other than above are not considered females of childbearing potential. Male patients must be sterile (biologically or surgically), commit to sexual abstinence or to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for four months following the last dose of study treatment. 10. Females of childbearing potential must have a negative serum pregnancy test during Screening and a negative urine or serum pregnancy test prior to receiving the first dose of study drug. Females who are at least two years postmenopausal or premenopausal with documented hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or permanent infertility due to alternate medical causes other than above are not considered females of childbearing potential. 11. Signed and dated Institutional Review Board (IRB)/Ethics Committee (EC)-approved ICF before any protocol-directed screening procedures are performed. Part 1b Pilot Food Effect Cohort - Specific Inclusion Criteria Patients who consent to participate in the pilot food effect cohort will also be required to meet the following inclusion criteria: 12. Able to eat a standardized high-fat, high-caloric or low-fat meal (as applicable to the food effect cohort assigned) within 25 minutes. Exclusion Criteria: A patient who meets any of the following exclusion criteria will be ineligible to participate in this study: 1. Treatment with any of the following: 1. Targeted therapy ≤ eight days or 5× the terminal phase elimination half-lives, whichever is shorter, prior to the first dose of study drug. 2. Systemic anticancer treatment (excluding targeted therapy as described above) ≤ 14 days prior to first dose of study drug. 3. Radiotherapy ≤ 28 days and palliative radiation ≤ 14 days prior to the first dose of study drug. If irradiated, lesions must have demonstrated clear-cut progression prior to being eligible for evaluation as target lesions. 4. Immunotherapy ≤ 28 days prior to the first dose of study drug. 5. Major surgery ≤ 28 days prior to the first dose of study drug. 2. Have any unresolved toxicity of Grade ≥ 2 from previous anti-cancer treatment, except for alopecia and skin pigmentation. Patients with chronic, but stable Grade 2 toxicities may be allowed to enroll after agreement between the Investigator and Sponsor Medical Monitor. 3. Have known or suspected brain metastases or spinal cord compression, unless the condition has been asymptomatic, treated with surgery and/or radiation, and has been stable without requiring escalating doses of corticosteroids or anti-convulsant medications for at least four weeks prior for the first dose of study drug. 4. Prior therapy with CID-078. 5. Known hypersensitivity to CID-078 or any drugs similar in structure or class. 6. Past medical history of interstitial lung disease, or any evidence of clinically active interstitial lung disease. Patients with sub-clinical pneumonitis who have received anti-cancer therapy (e.g., immunotherapy, ADC) previously can be included if their condition is stable without any medical intervention. 7. Patient has a history of congestive heart failure (CHF) Class III/IV according to the New York Heart Association (NYHA) Functional Classification or serious cardiac arrhythmias requiring treatment. 8. Heart rate corrected QT (QTc) interval (using Fridericia correction calculation) \> 470 msec. 9. Current treatment with medication known to prolong the QT/QTc interval (see examples from Table 28) or history of additional risk factors for Torsade de Pointes (e.g., heart failure, Grade ≥ 3 hypokalemia, family history of long QT syndrome). Patient who has adequately controlled condition or requires use of medications from Table 28 may be allowed upon agreement by the Investigator and Sponsor Medical Monitor. 10. Pregnant or lactating women. 11. History of another primary malignancy ≤ two years prior to starting study drug, except for adequately treated cancer (e.g., basal, or squamous cell carcinoma of the skin or cancer of the cervix in situ). 12. Malabsorption syndrome or other conditions (e.g., refractory nausea and vomiting, external biliary diversion, or any significant small bowel resection) that may interfere with adequate absorption of investigational product. 13. Uncontrolled intercurrent illness including, but not limited to, uncompensated respiratory, cardiac, hepatic, or renal disease, active infection (including untreated human immunodeficiency virus \[HIV\] and active clinical tuberculosis), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 14. Current endocrinopathies, unless in the opinion of the Investigator, endocrine complications are stable and well controlled and study participation does not jeopardize patient's health and wellbeing. Patients with asymptomatic endocrine disease on endocrine replacement therapy are eligible. 15. Active hepatitis B infection as defined by a positive hepatitis B surface antigen (HbsAg) test and detectable hepatitis B virus (HBV) DNA. Patients

SOCIAL WORKERS: Inclusion Criteria: * Working at the participating units. Exclusion Criteria: * None. PARENTS: Inclusion Criteria: * A parental role in relation to a child 0-17 years old (the participant does need not be a guardian or biological parent, can also be, for example, a partner to a parent). * A child welfare report has been filed for the child or the parent has reached out to the CWS themselves. Exclusion Criteria: * None.

Inclusion Criteria: * Adult patients with T2D of both sexes regardless of ethnicity, level of diabetes control and presence of complications. * Able to visit the study site 7 times * Able and willing to provide informed consent to the clinical and PRS parts of the study. Exclusion Criteria: * Any condition that may impact participation in a real-world study according to the treating physician. * People with a high frailty index as no benefit of therapeutic intensification has been demonstrated in these diabetic patients. * People who refuse to be informed of their cardiorenal risk score.

Inclusion Criteria: * Age: 13-35 years old(Patients with healthy siblings can be extended to 14-35 years of age) * Course of disease: \<24 months * Priority is given to patients who have never taken medicine or duration of drug use \< 2 weeks * No nuclear magnetic contraindications. Exclusion Criteria: * Family history of psychotic disorders, history of psychoactive substances abuse, alcohol dependence, or nicotine dependence * Have a major physical disease or infectious disease * History of coma and serious neurological disease 4.MRI contraindications.